Psoriasis Pipeline Update: JNJ-2113, A Novel Oral IL-23 Receptor Antagonist Peptide, Shows Promise in a Phase 2b Study

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

In The Pipeline: Phase 1, 2, and 3
In The Pipeline: Phase 1, 2, and 3
Psoriasis
In The Pipeline: Phase 1, 2, and 3
The Importance of Early Intervention for Psoriatic Arthritis
The Importance of Early Intervention for Psoriatic Arthritis
Psoriatic Arthritis
The Importance of Early Intervention for Psoriatic Arthritis
- G. Michael Lewitt, MD
The Latest on Systemic Agents for Psoriasis: A Q&A With Jashin J. Wu, MD, FAAD
The Latest on Systemic Agents for Psoriasis: A Q&A With Jashin J. Wu, MD, FAAD
Psoriasis
The Latest on Systemic Agents for Psoriasis: A Q&A With Jashin J. Wu, MD, FAAD
- Jashin J. Wu, MD, FAAD
Psleep: Psoriasis and Sleep
Psleep: Psoriasis and Sleep
Psoriasis
Psleep: Psoriasis and Sleep
- Annelies Isabelle Johanna Groen
- Jennifer Cather, MD